EGFR (T790M/C797S/L858R)
Sign in to save this workspaceEGFR · Variant type: compound · HGVS: p.T790M;p.C797S;p.L858R
Components
p.T790Mp.C797Sp.L858R
Drug response on this variant
| # | Drug | Inhibition on variant | Residual | KISS |
|---|---|---|---|---|
| 1 | Brigatinib | 100.0% | 0.0% | 82.96 |
| 2 | Fostamatinib | 98.5% | 1.5% | 96.74 |
| 3 | Dacomitinib | 94.3% | 5.7% | 97.99 |
| 4 | Afatinib | 92.4% | 7.6% | 98.50 |
| 5 | Osimertinib | 84.2% | 15.8% | 97.24 |
| 6 | Ceritinib | 81.7% | 18.3% | 95.44 |
| 7 | Lorlatinib | 81.0% | 19.0% | 97.24 |
| 8 | Pacritinib | 80.7% | 19.3% | 88.64 |
| 9 | Gilteritinib | 72.3% | 27.7% | 88.97 |
| 10 | Alectinib | 69.9% | 30.1% | 95.49 |
| 11 | Gefitinib | 66.3% | 33.7% | 99.25 |
| 12 | Bosutinib | 64.4% | 35.6% | 87.22 |
| 13 | Lazertinib | 59.5% | 40.5% | 97.47 |
| 14 | Neratinib | 43.7% | 56.3% | 93.18 |
| 15 | Nilotinib | 39.1% | 60.9% | 96.49 |
| 16 | Entrectinib | 32.2% | 67.8% | 93.69 |
| 17 | Pazopanib | 32.0% | 68.0% | 97.49 |
| 18 | Lapatinib | 27.3% | 72.7% | 99.25 |
| 19 | Canertinib | 23.2% | 76.8% | 96.49 |
| 20 | Ribociclib | 20.4% | 79.6% | 99.25 |
| 21 | Vemurafenib | 19.0% | 81.0% | 96.49 |
| 22 | Mobocertinib | 18.7% | 81.3% | 97.22 |
| 23 | Dasatinib | 17.2% | 82.8% | 87.97 |
| 24 | Cabozantinib | 16.2% | 83.8% | 92.73 |
| 25 | Vandetanib | 15.5% | 84.5% | 95.74 |
Wild-type vs variant — drug response delta
Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).
| Drug | Variant inh | WT inh | Δ (variant − WT) |
|---|---|---|---|
| Brigatinib | 100.0% | 98.5% | +1.5% |
| Fostamatinib | 98.5% | 97.8% | +0.8% |
| Dacomitinib | 94.3% | 99.8% | -5.5% |
| Afatinib | 92.4% | 100.0% | -7.5% |
| Osimertinib | 84.2% | 99.1% | -14.9% |
| Ceritinib | 81.7% | — | — |
| Lorlatinib | 81.0% | — | — |
| Pacritinib | 80.7% | — | — |
| Gilteritinib | 72.3% | 91.0% | -18.7% |
| Alectinib | 69.9% | — | — |
| Gefitinib | 66.3% | 99.9% | -33.6% |
| Bosutinib | 64.4% | 99.3% | -34.9% |
| Lazertinib | 59.5% | 100.0% | -40.5% |
| Neratinib | 43.7% | 100.0% | -56.3% |
| Nilotinib | 39.1% | — | — |
| Entrectinib | 32.2% | — | — |
| Pazopanib | 32.0% | — | — |
| Lapatinib | 27.3% | 99.2% | -71.9% |
| Canertinib | 23.2% | 98.4% | -75.3% |
| Ribociclib | 20.4% | — | — |
| Vemurafenib | 19.0% | — | — |
| Mobocertinib | 18.7% | 100.0% | -81.3% |
| Dasatinib | 17.2% | 97.9% | -80.7% |
| Cabozantinib | 16.2% | — | — |
| Vandetanib | 15.5% | 99.3% | -83.8% |
Annotations
Sign in to read and post annotations.
Loading…
Served from saifudeen2026@1.0.0 · API 0.1.0 · 16.2ms